Mind Medicine (MindMed) Inc. (MNMD)
NASDAQ: MNMD · Real-Time Price · USD
5.65
-0.13 (-2.17%)
At close: Apr 21, 2025, 4:00 PM
5.69
+0.05 (0.80%)
After-hours: Apr 21, 2025, 5:01 PM EDT
Mind Medicine (MindMed) Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Mind Medicine (MindMed) stock have an average target of 25.75, with a low estimate of 14 and a high estimate of 55. The average target predicts an increase of 356.16% from the current stock price of 5.65.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 7, 2025.
Analyst Ratings
The average analyst rating for Mind Medicine (MindMed) stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 5 | 5 | 4 |
| Buy | 5 | 4 | 5 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 10 | 10 | 10 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Baird | Baird | Buy Maintains $27 → $16 | Buy | Maintains | $27 → $16 | +183.44% | Mar 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $55 | Strong Buy | Reiterates | $55 | +874.31% | Mar 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $55 | Strong Buy | Reiterates | $55 | +874.31% | Jan 31, 2025 |
| Evercore ISI Group | Evercore ISI Group | Buy Initiates $23 | Buy | Initiates | $23 | +307.44% | Jan 28, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Initiates $20 | Strong Buy | Initiates | $20 | +254.30% | Dec 20, 2024 |
Financial Forecast
Revenue This Year
n/a
from 602.35M
Revenue Next Year
n/a
EPS This Year
-1.60
from -1.54
EPS Next Year
-1.74
from -1.60
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | 109.5M | ||
| Avg | n/a | n/a | 43.4M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.48 | -1.54 | -1.37 | ||
| Avg | -1.60 | -1.74 | -1.53 | ||
| Low | -1.64 | -1.87 | -1.88 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.